Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mecasermin Tercica.

Peter Norman1

  • 1Norman Consulting, 18 Pink Lane, Burnham, Bucks, UK. peter.norman2@btinternet.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 22, 2006
PubMed
Summary
This summary is machine-generated.

Mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1) therapy, treats growth failure in children with specific deficiencies or GH antibody issues. This rhIGF-1 treatment offers a new option for pediatric growth disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The lived experience of depression: a bottom-up review co-written by experts by experience and academics.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2023
Same author

Brexit and UK market exclusivities.

Pharmaceutical patent analyst·2018
Same author

Humira<sup>®</sup>: recent developments.

Pharmaceutical patent analyst·2017
Same author

Enbrel and etanercept biosimilars: a tale of two patent systems.

Pharmaceutical patent analyst·2017
Same author

Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Expert opinion on investigational drugs·2016
Same author

Humira: the impending patent battles over adalimumab biosimilars.

Pharmaceutical patent analyst·2016

Area of Science:

  • Pediatric Endocrinology
  • Growth Hormone Therapy
  • Pharmacology

Background:

  • Growth failure in children can stem from primary IGF-1 deficiency or GH gene deletion.
  • Neutralizing antibodies to growth hormone (GH) can impede effective GH therapy.
  • Alternative growth-promoting agents are crucial for non-responders to GH therapy.

Purpose of the Study:

  • To introduce mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1) therapy.
  • To outline the therapeutic application of rhIGF-1 in pediatric growth failure.
  • To address treatment challenges in children with GH resistance.

Main Methods:

  • Development and launch of mecasermin (rhIGF-1) by Tercica under license from Genentech.
  • Clinical application for growth failure in specific pediatric populations.

Related Experiment Videos

  • Management of patients with primary IGF-1 deficiency or GH antibody formation.

    • Main Results:

    • Mecasermin provides a therapeutic option for children with primary IGF-1 deficiency.
    • rhIGF-1 is indicated for growth failure in children with GH gene deletion and GH antibodies.
    • Successful development and market introduction of a novel rhIGF-1 treatment.

    Conclusions:

    • Mecasermin represents a significant advancement in treating pediatric growth failure.
    • rhIGF-1 therapy offers a viable solution for GH-unresponsive children.
    • The availability of mecasermin expands treatment paradigms for endocrine growth disorders.